The pps increased from 4c to 15c on excellent clinical trial update for VAXINIA and 5c to 8c on excellent clinical trial update for Azer-Cel. These are hardly considered "pips" and nothing unusual with how biotech start-up stock behave as the market value the MC based on further positive development of IP.
The problem is IMU is still heavily traded and short since entering the ASX 200 3-4 years ago so it get traded back down without sustain clinical trial updates. Had the clinical trial update for Azer-Cel been released when the pps was at 10c for months instead of dropping to 5c then the damage to the pps wouldn't have been as severe as now. Management think the stock is heavily trade and short partly due to the significantly high O/S so we will see "soon" with clinical trial updates from OASIS and Azer-Cel in the "coming months".
IMU Price at posting:
1.5¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)